Top

Published in:

01-01-2008 | Preclinical Study

TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells

Authors: Miriam B. Buck, Janet K. Coller, Thomas E. Mürdter, Michel Eichelbaum, Cornelius Knabbe

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

Response to treatment with the antiestrogen tamoxifen is variable and at least partially due to its highly complex metabolism. Tamoxifen is transformed by polymorphic and inducible cytochrome P450 enzymes to a large number of metabolites with varying biological activities. The estrogen receptor dependent growth inhibitory effect of antiestrogens is mediated by activation of antiproliferative Transforming Growth Factor beta (TGFβ) signal transduction pathways. The aim of the present study was to establish if TGFβ2 or TGFβ receptor II (TβRII), could be used as markers to assess the pharmacological potency of tamoxifen and its metabolites. Consequently, we analyzed the growth inhibitory effect of tamoxifen and its major metabolites and explored whether it correlated with their capacity to induce TGFβ2 and TβRII expression. Human breast cancer cells (MCF-7 and T47D) were treated with tamoxifen and tamoxifen metabolites and mRNA expression of TGFβ2 and TβRII was analyzed by quantitative RT-PCR. Only two metabolites 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen had significant antiproliferative activity and were able to induce TGFβ2 and TβRII. Plasma concentrations of these metabolites are usually very low in patients. However, even minor growth inhibitory effects at concentrations which are below the limit of quantification in plasma samples resulted in clearly discernible effects on expression of TGFβ2 and TβRII. Taken together, our data demonstrate that TGFβ2 and TβRII are very specific and sensitive biomarkers for the antiestrogenic activity of tamoxifen metabolites in breast cancer.

Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef

Boocock DJ, Brown K, Gibbs AH et al (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23:1897–1901PubMedCrossRef

Coller JK, Krebsfaenger N, Klein K et al (2002) The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157–167PubMedCrossRef

Coller JK, Krebsfaenger N, Klein K et al (2004) Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. Br J Clin Pharmacol 57:105–111PubMedCrossRef

Crewe HK, Ellis SW, Lennard MS, Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171–178PubMedCrossRef

Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–1075PubMedCrossRef

Mani C, Gelboin HV, Park SS et al (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21:645–656PubMed

Parte P, Kupfer D (2005) Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 33:1446–1452PubMedCrossRef

Kivisto KT, Villikka K, Nyman L et al (1998) Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 64:648–654PubMedCrossRef

10.

Lien EA, Anker G, Lonning PE et al (1990) Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 50:5851–5857PubMed

11.

Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764PubMed

12.

Coezy E, Borgna JL, Rochefort H (1982) Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317–323PubMed

13.

Etienne MC, Milano G, Fischel JL et al (1989) Tamoxifen metabolism: pharmacokinetic and in vitro study. Br J Cancer 60:30–35PubMed

14.

Jordan VC, Collins MM, Rowsby L, Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305–316PubMedCrossRef

15.

Johnson MD, Zuo H, Lee KH et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151–159PubMedCrossRef

16.

Lien EA, Solheim E, Lea OA et al (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49:2175–2183PubMed

17.

Lien EA, Solheim E, Ueland PM (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837–4844PubMed

18.

Knabbe C, Kopp A, Hilgers W et al (1996) Regulation and role of TGF beta production in breast cancer. Ann N Y Acad Sci 784:263–276PubMedCrossRef

19.

Zugmaier G, Ennis BW, Deschauer B et al (1989) Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 141:353–361PubMedCrossRef

20.

Moustakas A, Heldin CH (2005) Non-Smad TGF-beta signals. J Cell Sci 118:3573–3584PubMedCrossRef

21.

Brandt S, Kopp A, Grage B et al (2003) Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer. Anticancer Res 23:223–229PubMed

22.

Buck MB, Pfizenmaier K, Knabbe C (2004) Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol Endocrinol 18:1643–1657PubMedCrossRef

23.

Muller V, Jensen EV, Knabbe C (1998) Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Res 58:263–267PubMed

24.

Knabbe C, Zugmaier G, Schmahl M et al (1991) Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 14 Suppl 2:S15–S20

25.

Kopp A, Jonat W, Schmahl M, Knabbe C (1995) Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 55:4512–4515PubMed

26.

Gauthier S, Mailhot J, Labrie F (1996) New highly stereoselective synthesis of (Z)-4-hydroxytamoxifen and (Z)-4-hydroxytoremifene via McMurry reaction. J Org Chem 61:3890–3893PubMedCrossRef

27.

Coradini D, Cappelletti V, Granata G et al(1991) Activity of tamoxifen and its metabolites on endocrine-dependent and endocrine-independent breast cancer cells. Tumour Biol 12:149–158PubMedCrossRef

28.

Taylor CM, Blanchard B, Zava DT (1984) Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 44:1409–1414PubMed

29.

Fabian C, Tilzer L, Sternson L (1981) Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 2:381–390PubMedCrossRef

30.

Kemp JV, Adam HK, Wakeling AE, Slater R (1983) Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 32:2045–2052PubMedCrossRef

31.

Langan-Fahey SM, Tormey DC, Jordan VC (1990) Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26:883–888PubMedCrossRef

32.

MacCallum J, Cummings J, Dixon JM, Miller WR (2000) Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 82:1629–1635PubMedCrossRef

33.

Milano G, Etienne MC, Frenay M et al (1987) Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. Br J Cancer 55:509–512PubMed

34.

Murphy C, Fotsis T, Pantzar P et al (1987) Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). J Steroid Biochem 28:609–618PubMedCrossRef

35.

Crewe HK, Notley LM, Wunsch RM et al (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869–874PubMedCrossRef

36.

Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23–37PubMedCrossRef

37.

Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39PubMedCrossRef

38.

Dresser GK, Bailey DG (2002) A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol 9:191–198PubMed

39.

Kivisto KT, Kroemer HK, Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523–530PubMed

Title: TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells
Authors: Miriam B. Buck
Janet K. Coller
Thomas E. Mürdter
Michel Eichelbaum
Cornelius Knabbe
Publication date: 01-01-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9526-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?

Analysis of telomere damage by fluorescence in situ hybridisation on micronuclei in lymphocytes of breast carcinoma patients after radiotherapy

Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

Activation of protein kinase A (PKA) signaling mitigates the antiproliferative and antiinvasive effects of α-difluoromethylornithine in breast cancer cells

No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer